Standard BioTools Inc. (LAB)

Market Cap	497.57M
Revenue (ttm)	172.27M
Net Income (ttm)	-120.50M
Shares Out	379.82M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,015,397
Open	1.280
Previous Close	1.310
Day's Range	1.225 - 1.320
52-Week Range	0.920 - 2.320
Beta	1.32
Analysts	Buy
Price Target	2.50 (+90.84%)
Earnings Date	Aug 11, 2025

About LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provide...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 10, 2011
• Employees: 818
• Stock Exchange: NASDAQ
• Ticker Symbol: LAB
• Website: https://www.standardbio.com

Financial Performance

In 2024, Standard BioTools's revenue was $174.43 million, an increase of 64.03% compared to the previous year's $106.34 million. Losses were -$184.90 million, 147.7% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for LAB stock is "Buy." The 12-month stock price target is $2.5, which is an increase of 90.84% from the latest price.

Price Target

$2.5

(90.84% upside)

Analyst Consensus: Buy